5 completed, 2 recruiting, 2 terminated, 1 no longer available. 5 Phase 2, 4 Phase 3, 1 Phase 1.
By phase and status
Follow Prilenia: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
Pridopidine Phase 3 Study in Huntington's Disease Pridopidine, Placebo - Huntington Disease | Phase 3 | Recruiting | 400 | 2026-07-01 | 2026-11-19 |
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS Pridopidine, Placebo - Amyotrophic Lateral Sclerosis | Phase 3 | Recruiting | 500 | 2026-02-01 | 2026-11-17 |
HEALEY ALS Platform Trial - Regimen D Pridopidine Pridopidine, Matching Placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Completed | 163 | 2020-12-18 | 2023-08-23 |
PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD Pridopidine, Placebo - Huntington Disease | Phase 3 | Completed | 499 | 2020-10-16 | 2025-03-12 |
A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease Pridopidine, Placebo - Parkinson Disease | Phase 2 | Terminated | 23 | 2019-05-22 | 2022-07-01 |
A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease pridopidine (90 mg) - Health Volunteers, Huntington Disease | Phase 1 | Completed | 23 | 2017-04-19 | 2021-11-19 |
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease Pridopidine - Huntington's Disease | Phase 2 | Terminated | 248 | 2015-09-24 | 2021-09-17 |
A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease Pridopidine, Placebo - Huntington's Disease | Phase 2 | Completed | 408 | 2014-02-28 | 2021-07-19 |
Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease pridopidine - Huntington Disease | Phase 2 | Completed | 134 | 2011-03-24 | 2022-02-09 |
A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2) Pridopidine - Amyotrophic Lateral Sclerosis | | No longer available | | | 2025-05-18 |
Conditions studied
Huntington Disease (6) · Amyotrophic Lateral Sclerosis (3) · Dyskinesias (2) · Basal Ganglia Diseases (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Cognition Disorders (1) · Dementia (1) · Heredodegenerative Disorders, Nervous System (1) · Mental Disorders (1) · Movement Disorders (1) · Nervous System Diseases (1) · Neurocognitive Disorders (1) · Neurodegenerative Diseases (1) · Parkinson Disease (1)
Interventions
pridopidine (10)
Countries
United States (8) · Germany (6) · Canada (5) · France (5) · Italy (5) · Netherlands (5) · Poland (5) · United Kingdom (5) · Austria (3) · Spain (3) · Australia (2) · Belgium (2) · Czechia (2) · Russia (2) · Denmark (1)
Top investigators
Yael Cohen (2) · Merit Cudkowicz, MD (1)
Results publications
PMID 28826192, PMID 30563778, PMID 30572891, PMID 30776019, PMID 31356217, PMID 36811812, PMID 40067755, PMID 40913168, PMID 41406304
NIH funding
2015 (1), 2016 (1)